JMI LABS IS NOW PART OF LEARN MORE

Filter by Event: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2019

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2778

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data. Lead author: LM Deshpande, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2686

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2162

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2783

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae. Lead author: LR Duncan, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2787

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1847

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017)

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1873

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1843

Plazomicin Activity against Enterobacteriaceae Isolates Carrying Genes Encoding Extended-Spectrum β-Lactamases, Carbapenemases, and/or Aminoglycoside-Modifying Enzymes

Plazomicin Activity against Enterobacteriaceae Isolates Carrying Genes Encoding Extended-Spectrum β-Lactamases, Carbapenemases, and/or Aminoglycoside-Modifying Enzymes. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1872

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018)

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1883

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1876

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018)

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1882

In Vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecularly Characterized β-Lactamase Genes

In Vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecularly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1180

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1171

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1170

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1199

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1191

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018)

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1174

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1172

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1189

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#L0041